Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

ABT-737 synergizes with Bortezomib to kill melanoma cells.

Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG.

Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16.

2.

BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG.

J Invest Dermatol. 2009 Apr;129(4):964-71. doi: 10.1038/jid.2008.327. Epub 2008 Nov 6.

3.

ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.

Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE.

Mol Pharmacol. 2009 May;75(5):1231-9. doi: 10.1124/mol.108.052969. Epub 2009 Feb 25.

4.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
5.

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.

Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD.

Clin Cancer Res. 2012 Feb 1;18(3):783-95. doi: 10.1158/1078-0432.CCR-11-1166. Epub 2011 Dec 15.

6.

ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.

Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF.

J Pharmacol Exp Ther. 2012 Jun;341(3):859-72. doi: 10.1124/jpet.112.191536. Epub 2012 Mar 5.

7.

Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.

Okumura K, Huang S, Sinicrope FA.

Clin Cancer Res. 2008 Dec 15;14(24):8132-42. doi: 10.1158/1078-0432.CCR-08-1665.

8.

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

Rooswinkel RW, van de Kooij B, Verheij M, Borst J.

Cell Death Dis. 2012 Aug 9;3:e366. doi: 10.1038/cddis.2012.109.

9.

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.

Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG.

Oncotarget. 2017 Jul 18;8(29):46801-46817. doi: 10.18632/oncotarget.8695.

10.

A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.

Liu Y, Xie M, Song T, Sheng H, Yu X, Zhang Z.

Pigment Cell Melanoma Res. 2015 Mar;28(2):161-70. doi: 10.1111/pcmr.12325. Epub 2014 Dec 18.

PMID:
25324174
11.

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.

Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30.

12.

Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.

Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, Schmitz I, Kaufmann SH.

J Biol Chem. 2011 May 20;286(20):17682-92. doi: 10.1074/jbc.M110.189092. Epub 2011 Mar 22.

13.

Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.

Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.

14.

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, Norris DA, Shellman YG.

PLoS One. 2011;6(8):e24294. doi: 10.1371/journal.pone.0024294. Epub 2011 Aug 29.

15.

Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ.

Cancer Res. 2006 Oct 1;66(19):9636-45.

16.
17.

ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.

Touzeau C, Dousset C, Bodet L, Gomez-Bougie P, Bonnaud S, Moreau A, Moreau P, Pellat-Deceunynk C, Amiot M, Le Gouill S.

Clin Cancer Res. 2011 Sep 15;17(18):5973-81. doi: 10.1158/1078-0432.CCR-11-0955. Epub 2011 Aug 5.

18.

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

Pérez-Galán P, Roué G, Villamor N, Campo E, Colomer D.

Blood. 2007 May 15;109(10):4441-9. Epub 2007 Jan 16.

19.

Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

Hauck P, Chao BH, Litz J, Krystal GW.

Mol Cancer Ther. 2009 Apr;8(4):883-92. doi: 10.1158/1535-7163.MCT-08-1118.

20.

Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.

Kunami N, Katsuya H, Nogami R, Ishitsuka K, Tamura K.

Anticancer Res. 2014 Oct;34(10):5287-94.

PMID:
25275021

Supplemental Content

Support Center